Pura Vida Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

Pura Vida Investments’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-100,000	Closed	-$2.13M	–	207
2022 Q2	$2.13M	Sell	100,000 -89,363	-47%	-$1.83M	0.12%	136
2022 Q1	$3.65M	Buy	189,363 +50,700	+37%	+$858K	0.12%	137
2021 Q4	$2.88M	Buy	138,663 +26,339	+23%	+$524K	0.1%	136
2021 Q3	$2.68M	Sell	112,324 -1,737	-2%	-$39.6K	0.08%	177
2021 Q2	$3.11M	Sell	114,061 -31,683	-22%	-$892K	0.1%	140
2021 Q1	$4.22M	Buy	+145,744	New	+$4.55M	0.12%	126

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pura Vida Investments's ARQT Position: Q3 2022 in Review

Pura Vida Investments sold out of Arcutis Biotherapeutics (ARQT) in Q3 2022, closing a stake of 100,000 shares — an estimated $2.13M sold.

Pura Vida Investments first reported a position in ARQT in Q1 2021 and held it in 6 quarters. The position peaked at $4.22M in Q1 2021. 139 funds tracked by Wall St. Rank hold ARQT as of Q3 2022.

Pura Vida Investments reported no remaining Arcutis Biotherapeutics position as of Q3 2022 after selling out during the quarter.
Pura Vida Investments sold 100,000 Arcutis Biotherapeutics shares in Q3 2022, an estimated $2.13M.
Pura Vida Investments first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 6 quarters.
Pura Vida Investments's Arcutis Biotherapeutics position peaked at $4.22M in Q1 2021.
139 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2022.

Based on Pura Vida Investments's 13F filing for Q3 2022, filed 14 Nov 2022.